The filing lacks hard Q2 2026 financials (revenue, EPS), making a fundamental earnings read impossible. The strategic pivot to cannabinoid health sciences is a high-risk, long-duration catalyst with no near-term revenue visibility. Monitor for future 10-Q filings for actual financials and any FDA regulatory milestones for CannEpil®.
Price Chart
Executive Summary
Splash Beverage Group reported Q2 2026 results highlighting a 64% year-over-year reduction in loss from continuing operations for the first six months of 2026, driven by cost-cutting initiatives. The press release focuses on the company's strategic transformation toward cannabinoid health sciences under the new Endovia Health Sciences brand, including a global license for CannEpil® and a development collaboration with Lupvindol Biosciences. No specific revenue or EPS figures for Q2 2026 were provided in the filing, making a quantitative earnings assessment impossible, and the company remains in a loss position with a $3M market cap.
Key Facts
- Loss from continuing operations for H1 2026 was approximately $4M, down ~64% from ~$11M in H1 2025.
- Company entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform for drug-resistant epilepsy.
- Entered a development and collaboration agreement with Lupvindol Biosciences Ltd. for FDA veterinary product development.
- Company announced intention to rebrand as Endovia Health Sciences with ticker change effective August 24, 2026.
- No Q2 2026 revenue or EPS figures were disclosed in the press release or 8-K.
Financial Impact
Loss from continuing operations improved by ~$7M (64%) year-over-year for the first six months of 2026, but no quarterly revenue or EPS figures were provided.
Risk Factors
- No Q2 2026 revenue or EPS disclosed, preventing earnings quality assessment.
- Company remains in a loss position with a $3M market cap and high cash burn risk.
- Strategic transformation to cannabinoid health sciences is pre-revenue and faces significant regulatory and funding hurdles.
- Risk of delisting from NYSE American if continued listing standards are not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001114 |
| Document: e7875_ex99-1.htm | 0001731122-26-001114 |
| Document: 0001731122-26-001114-index-headers.html | 0001731122-26-001114 |
| Document: 0001731122-26-001114-index.html | 0001731122-26-001114 |
| Document: 0001731122-26-001114.txt | 0001731122-26-001114 |
| 8-K Data (Synthetic) | 0001731122-26-001114 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | DEFA14A | — | awaiting T+5 | — | — |
Aug 25, 2026 9w ago | 8-K | $0.4715 | awaiting T+5 | — | — |
Aug 21, 2026 9w ago | 8-K | $0.4376 | awaiting T+5 | — | — |
Aug 20, 2026 9w ago | 8-K | $0.4250 | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $0.4096 $0.4104 | ▲ +0.20% | ▲ +0.64% | — |
Aug 7, 2026 11w ago | S-1 | $0.4122 $0.3780 | ▲ +8.30% | ▲ +8.25% | — |
Aug 5, 2026 11w ago | 8-K | $0.4250 $0.4096 | ▼ −3.62% | ▼ −3.97% | — |
Jul 14, 2026 15w ago | 8-K | $0.1043 $0.0936 | ▼ −10.26% | ▼ −9.79% | — |
Jul 9, 2026 15w ago | 8-K | $0.1653 $0.0936 | ▲ +43.38% | ▲ +43.24% | — |
Jul 6, 2026 16w ago | 8-K | $0.2081 $0.1240 | ▼ −40.41% | ▼ −40.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers